However, a significant number of tumors exhibit low to moderate expression of HER2 (2+ with negative ISH/1+), which have traditionally been treated according to the recommendations for HR+ HER2-negative or triple-negative breast cancer (TNBC) [21]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.